NewGenIvf prices $1.25M public offering at $0.07 per share

NewGenIvf Group Limited (NASDAQ: NIVF) announced the pricing of a public offering expected to raise approximately $1.25 million in gross proceeds, before placement agent fees and other expenses.

The offering consists of 17,857,143 ordinary shares priced at $0.07 per share, or pre-funded warrants at $0.06999 each. The pre-funded warrants are immediately exercisable and remain exercisable until exercised in full. For each pre-funded warrant sold, the number of ordinary shares offered decreases on a one-for-one basis.

The transaction is expected to close on or about September 30, 2026, subject to customary closing conditions. The company said it plans to use the net proceeds for investment in K25.ai, debt restructuring, working capital including manufacturing and deployment of Nodexus machines in its cell-sorting business, and general corporate purposes.

Aegis Capital Corp. is serving as the exclusive placement agent. Han Kun Law Offices LLP is acting as U.S. counsel to the company, and Kaufman & Canoles, P.C. is acting as U.S. counsel to Aegis Capital Corp.

A registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission on August 20, 2026 was declared effective on September 28, 2026. The information is based on a company press release.

You May Also Be Interested In

• Star Fashion Culture closes $9.6M public offering of Class A shares
• Bluerock Acquisition Corp. II closes $172.5M IPO on Nasdaq
• AtlasClear insiders buy 815,000 shares for roughly $162,500